

## BRIEFING NOTE

# PRECIBING MOUNJARO (TIRZEPATIDE) IN GENERAL PRACTICE FOR WEIGHT LOSS

**AT PRESENT, AND UNTIL AT LEAST OCTOBER 2025, GENERAL PRACTITIONERS  
CANNOT PRESCRIBE MOUNJARO (TIRZEPATIDE) FOR WEIGHT LOSS**

Although NICE issued guidance in December 2024 that the NHS should provide Mounjaro (tirzepatide) to patients for weight loss from June 2025, presently it is unknown how NHS Leicester, Leicestershire and Rutland (NHS LLR) will be arranging for it to be given. The service will not start until at least **October 2025 (and possibly later)**.

NHS England has provided funding for a very limited number of patients to be prescribed tirzepatide (425 in total for this year for the whole of Leicester, Leicestershire and Rutland).

NHS LLR has also decided that patients cannot be referred for NHS care to Right to Choose providers like 'Oviva.'

The criteria are very strict (see below - for this year a BMI greater than 40, and at least four qualifying medical problems), but even so the number of eligible patients in LLR will be far in excess of the number being funded.

Patients with any further questions or concerns can contact NHS LLR:

**Room G30, Pen Lloyd Building, County Hall, Glenfield, Leicester, LE3 8TB**

Email: [llricb-llr.enquiries@nhs.net](mailto:llricb-llr.enquiries@nhs.net) Telephone: **0116 295 3405**

Year	Estimated Cohort Duration	Cohort	Cohort Access Groups	
			Comorbidities	BMI*
Year 1 2025/6	12 months	I	≥4 'qualifying' comorbidities: <ul style="list-style-type: none"> <li>• Hypertension</li> <li>• Dyslipidaemia</li> <li>• Obstructive Sleep Apnoea</li> <li>• Cardiovascular disease</li> <li>• Type 2 diabetes mellitus</li> </ul>	≥ 40
Year 2 2026/7	9 months	II	≥4 'qualifying' comorbidities: <ul style="list-style-type: none"> <li>• Hypertension</li> <li>• Dyslipidaemia</li> <li>• Obstructive Sleep Apnoea</li> <li>• Cardiovascular disease</li> <li>• Type 2 diabetes mellitus</li> </ul>	35 – 39.9
Year 2/3 2026 and 2027/8	15 months	III	3 'qualifying' comorbidities: <ul style="list-style-type: none"> <li>• Hypertension</li> <li>• Dyslipidaemia</li> <li>• Obstructive Sleep Apnoea</li> <li>• Cardiovascular disease</li> <li>• Type 2 diabetes mellitus</li> </ul>	≥ 40

*\*Use a lower BMI threshold (usually reduced by 2.5 kg/m2) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.*

**Version 3. Information Accurate as of 27 August 2025**

## ADVISE SUPPORT REPRESENT

Leicester, Leicestershire and Rutland Local Medical Committee

109 Station Road, Glenfield, Leicester, LE3 8GS

[enquiries@llrlmc.co.uk](mailto:enquiries@llrlmc.co.uk) [www.llrlmc.co.uk](http://www.llrlmc.co.uk) 0116 296 2950

Company Registration number: 06278584 Place of registration: England and Wales Registered office: Edward House, Grange Business Park, Leicester, LE8 6EP